Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives

SIMPLE SUMMARY: Personalized medicine has significantly changed the clinical outcome of oncogene-driven non-small cell lung cancer (NSCLC) due to the efficacy of molecular targeted therapies. Despite the advances in the management of this group of patients, the need for powerful biomarkers with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zografos, Eleni, Dimitrakopoulos, Foteinos-Ioannis, Koutras, Angelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563444/
https://www.ncbi.nlm.nih.gov/pubmed/36230877
http://dx.doi.org/10.3390/cancers14194954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563444/
https://www.ncbi.nlm.nih.gov/pubmed/36230877
http://dx.doi.org/10.3390/cancers14194954

Ejemplares similares